Form 8-K · Current report
Align Technology 8-K, filed Oct 28, 2026
- Filed
- CIK
- 0001097149
- Accession no.
- 0001097149-26-000077
Summary
Align Technology reported third-quarter 2026 total revenues of $1.015 billion, up 1.9% year over year, with Clear Aligner revenues up 4.2% and non-GAAP operating margin of 24.4%. The company guided fourth-quarter 2026 revenue to $1.00–$1.02 billion and full-year 2026 revenue to $4.11–$4.13 billion, while CEO Joe Hogan highlighted record doctor submitters and CFO John Morici described continued softness in discretionary dental spending.
Key points
- Q3'26 Clear Aligner volume rose 6.6% year over year to 690,635 cases.
- Q3'26 Imaging Systems and CAD/CAM Services revenues fell 7.6% year over year to $175.5 million.
- Q3'26 GAAP net income was $135.0 million, or $1.90 per diluted share; non-GAAP diluted EPS was $2.80.
- During Q3'26 Align repurchased about 627,300 shares at an average price of $164.73 and expects up to $300 million of repurchases in Q4'26.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On October 28, 2026, Align Technology, Inc. issued a press release and will hold a conference call regarding its financial results for its third quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. This information is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.